Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 213-224

  Armand, Jean Pierre ^a   Ribrag, Vincent ^a   Harrousseau, Jean Luc ^a   Abrey, Lauren ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain tumor; Glioma; Hodgkin's lymphoma; Lymphoma; Non Hodgkin's lymphoma; Procarbazine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALKYLATING AGENT; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; AZOPROCARBAZINE; BARBITURIC ACID DERIVATIVE; BENZYAZOXYPROCARBAZINE; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DECONGESTIVE AGENT; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; ETOPOSIDE; LOMUSTINE; MITOLACTOL; NIMUSTINE; PREDNISONE; PROCARBAZINE; PRODRUG; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ACUTE LEUKEMIA; ANEMIA; ASTROCYTOMA; AZOOSPERMIA; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; COMBINATION CHEMOTHERAPY; DEPRESSION; DNA SYNTHESIS INHIBITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG SYNTHESIS; DRUG TRANSFORMATION; DRUG USE; EOSINOPHILIA; FEMALE GENITAL SYSTEM FUNCTION; FOOD; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEADACHE; HEMOLYSIS; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSIVE CRISIS; INSOMNIA; LEUKOPENIA; LUNG CANCER; LUNG INFILTRATE; LYMPHOMA; MONOTHERAPY; NAUSEA; NERVOUSNESS; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGODENDROGLIOMA; PARESTHESIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA SYNTHESIS; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREMOR; VOMITING; WEAKNESS;

EID: 34250003708     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.213     Document Type: Review

References (78)

1. Abrey LE, Yahalom J, DeAngelis LM. 2000. Treatment for primary CNS lymphoma: the next step. J Clin Oncol, 18:3144-50.
2. [ACS] American Cancer Society. 2006. Cancer facts and figures 2006 [online]. Accessed on 28 December 2006. URL: http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf.
3. Berneis K, Kofler M, Bollag W, et al. 1963. The degradation of DNA by a new tumor inhibiting compound. Experientia, 19:132-3.
4. Bollag W, Grunberg E. 1963. The degradation of deoxyribonucleic acid by new tumour inhibiting compounds: the intermediate formation of hydrogen peroxide. Experientia, 19:130-1.
5. Brandes AA, Ermani M, Turazzi S, et al. 1999. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol, 17:645-50.
6. Brandes AA, Tosoni A, Vastola F, et al. 2004. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer, 101:2079-85.
7. Brunner KW, Young CW. 1965. A methylhydrazine derivative in Hodgkin's disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51 patients. Ann Intern Med, 63:69-86.
8. Buckner JC, Gesme D Jr, O'Fallon JR, et al. 2003. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol, 21:251-5.
9. Canellos GP, Anderson JR, Propert KJ, et al. 1992. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, MOPP alternating with ABVD. N Engl J Med, 327:1478-84.
10. Catenoix H, Honnorat J, Cartalat-Carel S, et al. 2006. [Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents.] Rev Neurol, 162:1069-75.
11. Chaar BT, Salem P, Petruska PJ. 2006. Procarbazine for non-Hodgkin's lymphoma. Leukemia Lymphoma, 47:637-40.
12. Chryssanthou CP, Wallach RC, Atchison M. 1983. Meiotic chromosomal changes and sterility produced by nitrogen mustard and procarbazine in mice. Fertil Steril, 39:97-102.
13. Corn BW, Marcus SM, Topham A, et al. 1997. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer, 79:2409-13.
14. Coyle T, Baptista J, Winfield J, et al. 1990. Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol, 8:2014-18.
15. DeAngelis LM, Delattre JY, Posner JB. 1989. Radiation-induced dementia in patients cured of brain metastases. Neurology, 39:789-96.
16. DeVita VT Jr, Canellos GP, Chabner B, et al. 1975. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet, 1:248-50.
17. Devita VT Jr, Serpick AA, Carbone PP. 1970. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med, 73:881-95.
18. Diehl V, Franklin J, Pfreundschuh M, et al. 2003. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348:2386-95.
19. Dufour C, Grill J, Lellouch-Tubiana A, et al. 2006. High-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocol. Eur J Cancer, 42:2939-45.
20. Duggan DB, Petroni GR, Johnson JL, et al. 2003. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J Clin Oncol, 21:607-14.
21. Engel C, Loeffler M, Schmitz H, et al. 2000. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol, 11:1105-14.
22. Erikson JM, Tweedie DJ, Ducore JM, et al. 1989. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res, 49:127-33.
23. Ezdinli EZ, Anderson JR, Melvin F, et al. 1985. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol, 3:769-75.
24. Ferme C, Mounier N, Casasnovas O, et al. 2006. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 107:4636-42.
25. Friedman HS. 2001. Alkylating agents in cancer chemotherapy and biotherapy. Chabner BA, Longo DL (eds). 4th edition. Philadelphia; Lippincott Williams & Wilkins, p 415.
26. Friedman HS, Johnson SP, Dong Q, et al. 1997. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res, 57:2933-6.
27. Glaser SL, Jarrett RF. 1996. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol, 9:401-6.
28. Gobbi PG, Broglia C, Levis A, et al. 2006. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Clin Cancer Res, 12:529-35.
29. Gobbi PG, Levis A, Chisesi T, et al. 2005. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol, 23:9198-207.
30. Grossman SA, Carson KA, Batchelor TT, et al. 2006. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res, 12:5174-81.
31. Herrlinger U, Brugger W, Bamberg M, et al. 2000. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology, 54:1707-8.
32. Hildebrand J, de Witte O, Sahmoud T. 1998. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - a phase II study. J Neurooncol, 37:155-60.
33. Hoang-Xuan K, Taillandier L, Chinot O, et al. 2003. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol, 21:2726-31.
34. Jeremic B, Jovanovic D, Djuric LJ, et al. 1992. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J Chemother, 4:123-6.
35. Kappelle AC, Postma TJ, Taphoorn MJ, et al. 2001. PCV chemotherapy for recurrent glioblastoma multiforme. Neurol, 56:118-20.
36. Kelly KM, Hutchinson RJ, Sposto R, et al. 2002. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol, 13 (Suppl 1): 107-11.
37. Kenis Y, De Smedt J, Tagnon HJ. 1966. The action of Natulan in 94 cases of solid tumors. Eur J Cancer, 2:51-7.
38. Kim L, Hochberg FR, Thornton AF, et al. 1996. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosur, 85:602-7.
39. Kyritsis AP, Yung WK, Jaeckle KA, et al. 1996. Combination of 6-thioguanine, procarbazine, lomustine and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery, 39:921-6.
40. Levin VA, Lamborn K, Wara W, et al. 2000. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neuro-oncol, 2:22-8.
41. Levin VA, Silver P, Hannigan J, et al. 1990. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas. NCOG 6G61 final report. Int J Radiat Oncol Biol Phys, 18:321-4.
42. Levin VA, Uhm JH, Jaeckle KA, et al. 2000. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res, 6:3878-84.
43. Levin VA, Wara WM, Davis RL, et al. 1985. Phase III comparison of BCNU and the combination of procarbazine, CCNU and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg, 63:218-23.
44. Livingston RB, Carter SK. 1970. Single agents in cancer chemotherapy. New York: IFI/Plenum Data Corp. p 318-36.
45. Loeffler M, Hasenclever D, Diehi V. 1998. Model based development of the BEACOPP regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol, 9:73-8.
46. Longo DL, Young RC, Hubbard SM, et al. 1984. Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med, 100:651-6.
47. Lowenbraun S, DeVita VT, Serpick AA. 1970. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer, 25:1018-25.
48. Luce JK, Gamble JF, Wilson HE, et al. 1971. Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer, 28:306-17.
49. McAllister LD, Doolittle ND, Guastadisegni PE, et al. 2000. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery, 46:51-61.
50. Malek FA, Moritz KU, Fanghanel J. 2003. Effects of prenatal procarbazine administration on intrauterine development in rats. Ann Anat, 185:117-19.
51. Martin H, Schubert JC. 1966. Cytostatic treatment of polycythemia vera with a methylbenzylhydrazine derivative. Dtsch Med Wochenschr, 91:55-7.
52. Massoud M, Armand JP, Ribrag V. 2004. Procarbazine in haematology: an old drug with a new life? Eur J Cancer, 40:1924-7.
53. Montoto S, Camos M, Lopez-Guillermo A, et al. 2000. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer, 88:2142-8.
54. [MRC] Medical Research Council Brain Tumor Working Party. 2001. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol, 19:509-18.
55. Newell D, Gescher A, Harland S, et al. 1987. N-methyl antitumor agents: a distinct class of anticancer drugs? Cancer Chemother Pharmacol, 19:91-102.
56. Newlands ES, Foster T, Zaknoen S. 2003. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer, 89:248-51.
57. Newton HB, Junck L, Bromberg J, et al. 1990. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurol, 40:1743-6.
58. Ng AK, Bernardo MV, Weller E, et al. 2002. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood, 100:1989-96.
59. Nicholson WM, Beard ME, Crowther D, et al. 1970. Combination chemotherapy in generalized Hodgkin's disease. Br Med J, 3:7-10.
60. Niitsu N, Umeda M. 1998. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma. Leukemia, 12:1457-60.
61. Pazdur R, Coia LR, Hoskins WJ, et al. 2003. Cancer management: a multidisciplinary approach. New York: The Oncology Group.
62. Pegg AE. 1990. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res, 50:6119-29.
63. Prados MD, Scott C, Curran WJ, Jr, et al. 1999. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol, 17:3389-95.
64. Preiss R, Baumann F, Regenthal R, et al. 2006. Plasma kinetics of procarbazine and azo-procarbazine in humans. Anti-Cancer Drugs, 17:75-80.
65. Rodriguez LA, Prados M, Silver P, et al. 1989. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer, 64:2420-3.
66. Rüffer JU, Ballova V, Glossmann J, et al. 2005. BEACOPP and COPP /ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma, 46:1561-7.
67. Rutinshauser A, Bollag W. 1963. Cytological investigations of a new class of cytotoxic agents methylhydrazine derivatives. Experientia, 19:131-2.
68. Sandberg-Wollheim M, Malmstrom P, Stromblad L, et al. 1991. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer, 68:22-9.
69. Sertoli MR, Santini G, Chisesi T, et al. 1994. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol, 12:1366-74.
70. Shpilberg O, Shiff J, Chetrit A, et al. 1994. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients. Cancer, 74:3029-33.
71. Stege EM, Kros JM, de Bruin HG, et al. 2005. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 103:802-9.
72. Supko JG, He X, Whitney C, et al. 2002. Pharmacokinetics of procarbazine and metabolites involved in its bioactivation in patients with recurrent anaplastic astrocytoma [abstract]. Proc Am Soc Clin Oncol, 21:2086.
73. Takenaka T, Mikuni C, Miura A, et al. 2000. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol, 30:146-52.
74. van den Bent MJ, Delattre J-Y, Brandes AA, et al. 2005. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. J Clin Oncol, 23:1503.
75. van den Bent MJ, Carpentier AF, Brandes AA, et al. 2006. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol, 24:2715-22.
76. Yung WK, Albright RE, Olson J, et al. 2000. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83:588-93.
77. Zbinden G. 1980. Unscheduled DNA synthesis in the testis, a secondary test for the evaluation of chemical mutagens. Arch Toxicol, 46:139-49.
78. Zeller P, Gutmann H, Hegedus B, et al. 1963. Methylhydrazine derivatives, a new class of cytotoxic agents. Experientia, 19:129.